What it is
Cartalax is a Khavinson-class bioregulator discussed in Russian cartilage and joint research. Human protocol data outside that literature are limited.
Evidence boundary
Regional bioregulator literature with limited independent replication. Do not present a fixed human schedule as established fact.
Preparation and measurement
Reconstitution: 20 mg vial + 3 mL BAC = 6.67 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Cycle | 500 mcg | 7.5 U (0.075 mL) | Daily during cycle | 3.5 mg/week |
Cycle
- Dose
- 500 mcg
- Draw / measure
- 7.5 U (0.075 mL)
- Frequency
- Daily during cycle
- Weekly total
- 3.5 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Standard cycle: Daily dose during 10–20 day active phase, 5–6 month break.
-
Joint symptom notes in the source literature
-
Injection-site reactions
Practical rules
- Do not merge it with generic joint-recovery stacks.
- Rotate sites.
Related protocols
BPC-157 Peptide Protocol & DosingKPV Peptide Protocol & DosingGHK-Cu Peptide Protocol & DosingARA-290 Peptide Protocol & Dosing Supply & lot verification
Availability and batch-linked COA records for Cartalax Peptide Protocol & Dosing are kept with the current product listing.
View availability & COA → Verification notes